Myeloid cell-derived coagulation tissue factor is associated with renal tubular damage in mice fed an adenine diet.
Adenine
/ toxicity
Animals
Fibrin Fibrinogen Degradation Products
/ metabolism
Glomerular Filtration Rate
Humans
Kidney Tubules
/ drug effects
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Myeloid Cells
/ metabolism
Renal Insufficiency, Chronic
/ chemically induced
Thromboplastin
/ physiology
Toxins, Biological
/ metabolism
Uremia
/ physiopathology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 06 2021
09 06 2021
Historique:
received:
26
10
2020
accepted:
13
05
2021
entrez:
10
6
2021
pubmed:
11
6
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Patients with chronic kidney disease (CKD) commonly exhibit hypercoagulability. Increased levels of uremic toxins cause thrombogenicity by increasing tissue factor (TF) expression and activating the extrinsic coagulation cascade. TF is induced in monocytes and macrophages under pathological conditions, such as inflammatory diseases. However, the role of monocyte myeloid cell TF in CKD progression remains unclear. We aimed to clarify this issue, and the present study found that patients with CKD had elevated levels of D-dimer, a marker of fibrin degradation, which was associated with decreased estimated glomerular filtration rate and increased serum levels of uremic toxins, such as indoxyl sulfate. In vitro studies showed that several uremic toxins increased cellular TF levels in monocytic THP-1 cells. Mice with TF specifically deleted in myeloid cells were fed an adenine diet to cause uremic kidney injury. Myeloid TF deletion reduced tubular injury and pro-inflammatory gene expression in the kidneys of adenine-induced CKD but did not improve renal function as measured by plasma creatinine or blood urea nitrogen. Collectively, our findings suggest a novel concept of pathogenesis of coagulation-mediated kidney injury, in which elevated TF levels in monocytes under uremic conditions is partly involved in the development of CKD.
Identifiants
pubmed: 34108522
doi: 10.1038/s41598-021-91586-5
pii: 10.1038/s41598-021-91586-5
pmc: PMC8190319
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
Toxins, Biological
0
fibrin fragment D
0
Thromboplastin
9035-58-9
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12159Références
Vascul Pharmacol. 2014 Aug;62(2):57-62
pubmed: 24858575
Toxicol Appl Pharmacol. 2011 Feb 1;250(3):256-62
pubmed: 21070799
Semin Thromb Hemost. 2006 Feb;32(1):11-23
pubmed: 16479458
J Thromb Haemost. 2010 Oct;8(10):2122-32
pubmed: 20626618
J Clin Invest. 2012 Feb;122(2):558-68
pubmed: 22214850
Arch Toxicol. 2019 Jan;93(1):121-136
pubmed: 30324315
Annu Rev Physiol. 2017 Feb 10;79:449-469
pubmed: 28192060
Nephrology (Carlton). 2019 Sep;24(9):943-950
pubmed: 30407693
JAMA. 2019 Oct 1;322(13):1294-1304
pubmed: 31573641
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):13-24
pubmed: 30580574
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):603-613
pubmed: 28348030
BMC Nephrol. 2017 Jan 25;18(1):35
pubmed: 28122514
Toxins (Basel). 2017 Jan 29;9(2):
pubmed: 28146081
Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F654-F659
pubmed: 30672316
Sci Transl Med. 2017 Nov 22;9(417):
pubmed: 29167396
Kidney Int. 2003 May;63(5):1934-43
pubmed: 12675874
Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F737-50
pubmed: 23283995
Am J Transl Res. 2015 Nov 15;7(11):2326-34
pubmed: 26807180
Kidney Int. 2018 Jun;93(6):1442-1451
pubmed: 29605094
Toxins (Basel). 2018 Oct 12;10(10):
pubmed: 30322010
Thromb Res. 2020 Feb;186:75-77
pubmed: 31901643
Sci Rep. 2018 Jul 18;8(1):10858
pubmed: 30022146
Eur J Pharmacol. 2018 Feb 5;820:65-76
pubmed: 29229532
Heart. 1999 Feb;81(2):134-40
pubmed: 9922347
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1525-33
pubmed: 27283743
Kidney Int. 2005 Apr;67(4):1315-29
pubmed: 15780084
J Cell Mol Med. 2019 Feb;23(2):1268-1279
pubmed: 30485646
Scand J Immunol. 2013 May;77(5):339-49
pubmed: 23421536
Hematol J. 2001;2(1):18-25
pubmed: 11920229
Cardiovasc Diagn Ther. 2018 Oct;8(5):581-593
pubmed: 30498683
J Am Soc Nephrol. 2018 Mar;29(3):1063-1072
pubmed: 29343519
Nat Rev Nephrol. 2016 Feb;12(2):94-109
pubmed: 26592189
Biochem Biophys Res Commun. 2017 Jan 29;483(1):547-552
pubmed: 28025140
Semin Immunopathol. 2012 Jan;34(1):133-49
pubmed: 21971685
Semin Thromb Hemost. 2010 Feb;36(1):34-40
pubmed: 20391294
Thromb Haemost. 2009 Apr;101(4):656-64
pubmed: 19350108
BMJ Open. 2017 Jun 1;7(5):e014294
pubmed: 28576889
Sci Rep. 2018 Oct 2;8(1):14684
pubmed: 30279491
PLoS One. 2013 Sep 13;8(9):e74401
pubmed: 24058557
Clin Exp Nephrol. 2021 Apr;25(4):325-364
pubmed: 33606126
Blood. 2010 Aug 5;116(5):806-14
pubmed: 20410508
BMC Nephrol. 2013 May 30;14:116
pubmed: 23718816
Kidney Int. 2018 Sep;94(3):567-581
pubmed: 30078514
Circ J. 2010 Jan;74(1):3-12
pubmed: 19996531
Kidney Int. 2007 Feb;71(3):266-71
pubmed: 17149371
Kidney Int. 2013 Oct;84(4):733-44
pubmed: 23636172
Toxins (Basel). 2017 Dec 28;10(1):
pubmed: 29283413
Thromb Res. 2014 Dec;134(6):1350-7
pubmed: 25307422
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725
pubmed: 29437578
Thromb Haemost. 2005 Nov;94(5):1028-34
pubmed: 16363246